PLA2g6 Mouse Model for Parkinson's Disease Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease (PD) lack effective methods to prevent or stop the progression of the disease, and there is a need for cellular and animal models to identify therapeutic agents that can modulate PD and treat or prevent it, as the underlying mechanism of dopaminergic neuron demise in PD is not fully understood, particularly regarding the Pla2g6 gene and its variants.
Innovation Solution
A novel PLA2g6 mouse model (KOEx2) is created with genetic deletion of Exon 2, leading to a loss of dopaminergic neurons and PD-like motor dysfunction, which can be improved by L-DOPA, and further analysis reveals a causal relationship between impaired store-operated Ca2+ entry (SOCE) and the loss of dopaminergic neurons, allowing for the development of methods to screen compounds affecting the SOCE pathway and treat PD-related deficits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (levodopa and dopamine agonists) are used to manage motor symptoms, then early motor symptoms are improved, but the disease progression cannot be stopped and dyskinesia complications eventually occur
Solution Approach 1:
The patent uses the PLA2g6 mouse model as an intermediary system to study the underlying mechanisms of PD. By creating a genetic model that specifically targets PLA2g6 function, researchers can identify compounds that modulate the disease mechanism without immediately treating human patients with potentially harmful side effects. This intermediary model allows for safer exploration of therapeutic mechanisms.
Solution Approach 2:
The patent employs preliminary screening of compounds using the PLA2g6 mouse model and cellular assays before advancing to clinical trials. This preliminary action in animal models allows identification of compounds that can activate SOCE and protect dopaminergic neurons before human testing, potentially preventing the development of dyskinesia complications that occur with conventional treatments.
2Loss of information
If more research is conducted to understand the underlying mechanism of dopaminergic neuron demise, then better treatments may be identified, but time and resources are consumed without immediate therapeutic benefit
Solution Approach 1:
The patent changes the parameter of research efficiency by using a genetically defined mouse model (PLA2g6 knockout) rather than traditional PD models. This specific genetic parameter allows for more direct investigation of the PLA2g6-SOCE-dopaminergic neuron pathway, accelerating the rate of mechanistic understanding while maintaining focus on therapeutically relevant questions.
Solution Approach 2:
The patent creates an intermediary research system using cellular models and the PLA2g6 mouse model that bridge the gap between basic mechanistic studies and clinical applications. These intermediary systems allow rapid screening and validation of compounds that activate SOCE, translating mechanistic insights into potential therapies more quickly than traditional approaches.
3Loss of information
If a genetic mouse model with PLA2g6 deletion is created to study PD mechanisms, then insight into dopaminergic neuron loss is gained, but the model complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts the specific genetic element (PLA2g6 gene) responsible for the disease mechanism and creates a targeted knockout model. By removing only this specific gene rather than creating complex multi-gene models or using less specific induction methods, the model achieves high mechanistic relevance while maintaining relative simplicity in generation and maintenance.
Data Source
AI summary
This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell. This disclosure also provides methods of treating or preventing PD-related deficit(s) in an animal by characterizing a compound as a SOCE activator using the screening methods and then administering an effective amount of the compound to an animal. This disclosure also provides methods of restoring normal store-operated Ca2+ entry (SOCE) pathway and ER Ca2+ in a cell, comprising introducing a caspase-3 cleavage-resistant PLA2g6 protein into the cell. This disclosure also provides methods of treating or preventing a PD-related deficit(s) in an animal, comprising administering a caspase-3 cleavage-resistant PLA2g6 protein to the animal.